RIPK2-IN-7

• Description:

  RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM) . RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα) . RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) [1].

• UNSPSC:

  12352005

• Target:

  NOD-like Receptor (NLR) ; RIP kinase; TNF Receptor

• Related Pathways:

  Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  NC1=C2C(C3=C(C=C(C=C3)C)F)=CN([C@H]4CC[C@H](CC4)N)C2=NC=N1

• Molecular Formula:

  C19H22FN5

• Molecular Weight:

  339.41

• References & Citations:

  [1]Yuan X, et al. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs) . J Med Chem. 2022 Jul 14;65 (13) :9312-9327.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  RIPK2

• CAS Number:

  [2789711-40-4]